Pfizer to cut another 200 jobs

By Katrina Megget

- Last updated on GMT

Related tags: Pfizer

Pfizer is already cutting jobs in relation to its failed Exubera
with the announcement that some 200 jobs are to go at the drug
giant's Portage and Kalamazoo sites, according to local media
reports.

The Kalamazoo Gazette reported on Friday that the downsizing would reflect a 6.6 per cent reduction in the 3000-strong workforce amid "ongoing changes in demand for the drug-maker's products"​. Sixty of the positions would be lost from Portage in relation to the abandoned inhaled insulin Exubera, the Kalamazoo Gazette said. Information on other affected areas was not available. "What it boils down to is Kalamazoo manufacturing is not immune to the challenges of the competitive global environment. So we must focus on those activities where we can make the strongest contribution to Pfizer's business,"​ Pfizer spokesman Rick Chambers told the Kalamazoo Gazette. According to media reports, the job cuts are additional to an early announcement that 250 jobs were expected to be lost next year in drug safety. The moves reflect Pfizer's overhaul of the business and the cost-cutting strategies that were announced earlier this year. The company is in the process of reducing its staff by almost 10,000 - 10 per cent of its global workforce - in a bid to save $1bn (€0.7bn) by the end of 2008. Meanwhile, Pfizer announced plans to reduce its number of manufacturing sites from 93 to 48 by the end of next year including the closure of five R & D sites and the relocation of projects amongst remaining facilities and external sites. The Kalamazoo site was a target in that portfolio, though Pfizer said in January the site would continue to maintain a large manufacturing and animal health presence. Before the announcement a fortnight ago that Exubera would be dropped - at a cost of $2.8bn - production cuts had already been made by Pfizer's Exubera manufacturing partners, West Pharmaceutical Services and Consort Medical (formerly Bespak), reflecting the disappointing revenues the formerly touted blockbuster drug was bringing in. In June, Bespak announced it would cut 160 jobs as a result of the slow uptake of the drug, and then in August, West announced it would scale back production in the third quarter of this year to one shift per day. A Pfizer spokesman was unavailable for comment at time of publishing. Some of the latest job cuts in Kalamazoo would be achieved through attrition, the Kalamazoo Gazette reported.

Related news

Show more

Related products

show more

A Culture of Innovation as a Differentiation

A Culture of Innovation as a Differentiation

Softigel by Procaps | 06-Dec-2021 | Product Presentation

We create safe, effective and differentiated pharmaceutical solutions and this has been our goal since day 1. The main driver of our growth is innovation...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Follow us

Products

View more

Webinars